Evidence map›Paper›PMID 31345237›Full record

ArticleJournal of translational medicine2019

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.

Patrick Tjok Joe, Ioanna Christopoulou, Lien van Hoecke, Bert Schepens, Tine Ysenbaert, Carlo Heirman, Kris Thielemans, Xavier Saelens, Joeri L Aerts

Abstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Dendritic Cell-Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022
    Review
  16. mRNA cancer vaccines: Advances, trends and challenges.Acta pharmaceutica Sinica. B · 2022
    Review
  17. Review
  18. Messenger RNA-Based Vaccines Against Infectious Diseases.Current topics in microbiology and immunology · 2022
    Review
  19. Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Patrick Tjok JoeLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Jette, Belgium.ORCID 0000-0001-7890-1667
Ioanna ChristopoulouVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Lien van HoeckeVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Bert SchepensVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Tine YsenbaertVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Carlo HeirmanLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Jette, Belgium.
Kris ThielemansLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Jette, Belgium.
Xavier SaelensVIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
Joeri L AertsLaboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel (VUB), Jette, Belgium. Joeri.Aerts@vub.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent human influenza vaccines lack the adaptability to match the mutational rate of the virus and therefore require annual revisions. Because of extensive manufacturing times and the possibility that antigenic alterations occur during viral vaccine strain production, an inherent risk exists for antigenic mismatch between the new influenza vaccine and circulating viruses. Targeting more conserved antigens such as nucleoprotein (NP) could provide a more sustainable vaccination strategy by inducing long term and heterosubtypic protection against influenza. We previously demonstrated that intranodal mRNA injection can induce potent antigen-specific T-cell responses. In this study, we investigated whether intranodal administration of mRNA encoding NP can induce T-cell responses capable of protecting against a heterologous influenza virus challenge.

methodsBALB/c mice were immunized in the inguinal lymph nodes with different vaccination regimens of mRNA encoding NP. Immune responses were compared with NP DNA vaccination via IFN-γ ELISPOT and in vivo cytotoxicity. For survival experiments, mice were prime-boost vaccinated with 17 µg NP mRNA and infected with 1LD50 of H1N1 influenza virus 8 weeks after boost. Weight was monitored and viral titers, cytokines and immune cell populations in the bronchoalveolar lavage, and IFN-γ responses in the spleen were analyzed.

resultsOur results demonstrate that NP mRNA induces superior systemic T-cell responses against NP compared to classical DNA vaccination. These responses were sustained for several weeks even at low vaccine doses. Upon challenge infection, vaccination with NP mRNA resulted in reduced lung viral titers and improved recovery from infection. Finally, we show that vaccination with NP mRNA affects the immune response in infected lungs by lowering immune cell infiltration while increasing the fraction of T cells, monocytes and MHC II

conclusionsThese findings suggest that intranodal vaccination with NP mRNA induces cross-strain immunity against influenza, but also highlight a paradox of influenza immunity, whereby robust immune responses can provide protection, but can also transiently exacerbate symptoms during infection.

Indexed as

AnimalsAntibodies, ViralAntigensBronchoalveolar LavageDogsFemaleHumansInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesInterferon-gammaMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CNucleoproteinsOrthomyxoviridae InfectionsPlasmidsAntibodies, ViralAntigensInfluenza VaccinesInterferon-gammaNucleoproteinsRNA, MessengerInfluenzaIntranodalmRNANucleoproteinT cellUniversal vaccine

Identifiers

PMID31345237
PMCPMC6659201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.